Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Tilray Brands, Inc. TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. The... see more

NDAQ:TLRY - Post Discussion

Tilray Brands, Inc. > How schedule 3 will effect Tilray
View:
Post by Vegas63 on Mar 17, 2024 9:53am

How schedule 3 will effect Tilray

Some posters ask frequently  "   how does cannabis  going to a schedule 3 effect Tilray " ??

First lets look at what schedule 3 drugs in the United States  are ;

Schedule III  ; Drugs with low to moderate  potential for abuse and / or addiction  .,..
Some examples of Schedule 3 drugs are ;

- Products containing less than 90 milligrams of codeine per dosage unit ( Tylenol with codeiine )
- Ketamine
- Anabolic steroids
- Testosterone

these are only a few samples of schedule 3 drugs in the United States ,, you can look it up on the internet to see more if you want ,,,

Once cannabis ( marijuana ) joins the list of schedule 3 drugs that's it ... it is now a schedule 3
drug  according to the law ..


Some states have different lists of schedule 3 drugs but Cannabis will be on it ,,.,

On January 5 , 2024 , the Food and Drug Administration ( FDA ) authorized the state of Florida
to import prescription drugs from Canada ..,. to take advantage of  LOWER costs Canada is producing and selling  ,,.,.

the drugs Florida will want to import include those that treat HIV/AIDS , mental health  conditions , prostate cancer and othe cancers ,,, you can look at the  whole list if you go on the internet ,,,

other States want in on the importing of Canada's prescription drugs including Cailforna

as Florida has stated it would save them hundreds of millions by importing Prescription drugs from Canada ..,.

I am not a corperate lawyer but I am sure Tilray has coperate lawyers that have looked into 
what prescription drugs  Florida will be importing that are schedule 3 drugs ,,.,

as mentioned if the FDA  has approved any schedule 3 drugs to be imported to Florida from Canada a Precedent has been set ...  meaning Cannibis /  Marijuana   is just another schedule 3 drug if Florida wants to import they legally would be able to ...
Comment by Oldweed on Mar 17, 2024 11:03am
That is actually an interesting perspective, you may be on to something there! The medical side of the market may benefit Canadian LP's if they can tap into it. The assumtion though is that big pharma will inflate the prices in the US, so that is dependent on pharma entry into the sector. Wouldn't that be ironic if pharma entered through Tilray lpl. I'm sure that will be clarified in ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities